Gerardo Gonzalez1, Gregory DiGirolamo2, Mauricio Romero-Gonzalez3, David Smelson4, Douglas Ziedonis4, Monika Kolodziej4. 1. Division of Addiction Psychiatry, University of Massachusetts Medical School, USA; VA Central Western Massachusetts Healthcare System, USA; MAYU of New England, USA. Electronic address: gerardo.gonzalez@umassmed.edu. 2. Division of Addiction Psychiatry, University of Massachusetts Medical School, USA; College of the Holy Cross, USA. 3. Division of Addiction Psychiatry, University of Massachusetts Medical School, USA; MAYU of New England, USA. 4. Division of Addiction Psychiatry, University of Massachusetts Medical School, USA.
Abstract
BACKGROUND: Opioid use disorders are considered a serious public health problem among young adults. Current treatment is limited to long-term opioid substitution therapy, with high relapse rates after discontinuation. This study evaluated the co-administration of memantine to brief buprenorphine pharmacotherapy as a treatment alternative. METHODS: 13-week double-blind placebo-controlled trial evaluating 80 young adult opioid dependent participants treated withbuprenorphine/naloxone16-4mg/day and randomized tomemantine (15mg or 30mg) or placebo. Primary outcomes were a change in the weekly mean proportion of opioid use, and cumulative abstinence rates after rapid buprenorphine discontinuation on week 9. RESULTS:Treatment retention was not significantly different between groups. The memantine 30mg group was significantly less likely to relapse and to use opioids after buprenorphine discontinuation. Among participants abstinent on week 8, those in the memantine 30mg group (81.9%) were significantly less likely to relapse after buprenorphine was discontinued compared to the placebo group (30%) (p<0.025). Also, the memantine 30mg group had significantly reduced opioid use (mean=0, SEM±0.00) compared to the placebo group (mean=0.33, SEM±0.35; p<0.004) during the last 2 weeks of study participation. CONCLUSIONS:Memantine 30mg significantly improved short-term treatment with buprenorphine/naloxone for opioid dependent young adults by reducing relapse and opioid use after buprenorphine discontinuation. Combined short-term treatment with buprenorphine/naloxone may be an effective alternative treatment to long-term methadone or buprenorphine maintenance in young adults. Published by Elsevier Ireland Ltd.
RCT Entities:
BACKGROUND: Opioid use disorders are considered a serious public health problem among young adults. Current treatment is limited to long-term opioid substitution therapy, with high relapse rates after discontinuation. This study evaluated the co-administration of memantine to brief buprenorphine pharmacotherapy as a treatment alternative. METHODS: 13-week double-blind placebo-controlled trial evaluating 80 young adult opioid dependent participants treated with buprenorphine/naloxone 16-4mg/day and randomized to memantine (15mg or 30mg) or placebo. Primary outcomes were a change in the weekly mean proportion of opioid use, and cumulative abstinence rates after rapid buprenorphine discontinuation on week 9. RESULTS: Treatment retention was not significantly different between groups. The memantine 30mg group was significantly less likely to relapse and to use opioids after buprenorphine discontinuation. Among participants abstinent on week 8, those in the memantine 30mg group (81.9%) were significantly less likely to relapse after buprenorphine was discontinued compared to the placebo group (30%) (p<0.025). Also, the memantine 30mg group had significantly reduced opioid use (mean=0, SEM±0.00) compared to the placebo group (mean=0.33, SEM±0.35; p<0.004) during the last 2 weeks of study participation. CONCLUSIONS:Memantine 30mg significantly improved short-term treatment with buprenorphine/naloxone for opioid dependent young adults by reducing relapse and opioid use after buprenorphine discontinuation. Combined short-term treatment with buprenorphine/naloxone may be an effective alternative treatment to long-term methadone or buprenorphine maintenance in young adults. Published by Elsevier Ireland Ltd.
Entities:
Keywords:
Buprenorphine; Early relapse; Memantine; Opioid dependence; Young adults
Authors: Roger D Weiss; Margaret L Griffin; Monika E Kolodziej; Shelly F Greenfield; Lisa M Najavits; Dennis C Daley; Heidi Ray Doreau; John A Hennen Journal: Am J Psychiatry Date: 2007-01 Impact factor: 18.112
Authors: Adam Bisaga; Maria A Sullivan; Wendy Y Cheng; Kenneth M Carpenter; John J Mariani; Frances R Levin; Wilfrid N Raby; Edward V Nunes Journal: Drug Alcohol Depend Date: 2011-06-28 Impact factor: 4.492
Authors: Adam Viera; Daniel J Bromberg; Shannon Whittaker; Bryan M Refsland; Milena Stanojlović; Kate Nyhan; Frederick L Altice Journal: Epidemiol Rev Date: 2020-01-31 Impact factor: 6.222
Authors: Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Jeanette M Tetrault; Julia Shi; Ralitza Gueorguieva; Brian Pittman; John H Krystal Journal: Neuropsychopharmacology Date: 2019-10-07 Impact factor: 7.853
Authors: Sara J Becker; Kelli Scott; Sarah A Helseth; Kristin J Danko; Ethan M Balk; Ian J Saldanha; Gaelen P Adam; Dale W Steele Journal: J Subst Abuse Treat Date: 2021-05-29